TAS::75 0872::TAS SMARTT (11-8470187)

塔斯马尼亚::75 0872::塔斯马特 (11-8470187)

• 批准号: 9004269
• 负责人: HANNA NG
• 金额: $ 199.51万
• 依托单位: SRI INTERNATIONAL
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-11-08 至 2015-05-07
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9004269
• 关键词: Accreditation; Animals; Basic Science; Biodistribution; Canis familiaris; Client; Clinic; Clinical; Clinical Research; Communities; Consult; Contractor; Contracts; Data; Development; Government; Guidelines; Heart Diseases; Hematological Disease; Human; Individual; International; Knowledge; Lung diseases; National Heart, Lung, and Blood Institute; Oryctolagus cuniculus; Performance; Pharmaceutical Preparations; Pharmacology; Pharmacology and Toxicology; Phase; Preclinical Testing; Qualifying; Regulation; Reporting; Request for Proposals; Research; Research Design; Research Institute; Research Personnel; Resources; Rodent; Safety; Science; Scientist; Services; System; Testing; Therapeutic; Therapeutic Intervention; Toxicology; Translational Research; Translations; Treatment Protocols; United States National Institutes of Health; Work; animal care; case-by-case basis; cost effective; design; drug candidate; drug development; experience; flexibility; good laboratory practice; in vitro Assay; interest; meetings; nonhuman primate; novel; pre-clinical; preclinical study; programs; response; small molecule; symposium

In response to Request of Proposal (RFP), NHLBI-HV-1 0-11, SRI International (SRI, formerly Stanford Research Institute) proposes to act as a flexible and responsive resource contractor as the Pharmacology and Toxicology Center (PTC) to support the Science Moving towArds Research Translation and Therapy (SMARTT) program of the National Heart, Lung, and Blood Institute (NHLBI). The purpose of the SMARTT program is to provide resources, such as consulting, manufacturing, pharmacology and toxicology testing, preclinical and early-phase clinical study design support, and administrative and regulatory expertise, to assist translation to the clinic of novel synthetic, natural, or biologic therapeutic interventions arising in the scientific community for the treatment of heart, lung, and blood diseases.

为响应提案请求（RFP）， NHLBI- hv - 10 -11， SRI国际（SRI，前斯坦福研究所）提议作为药理学和毒理学中心（PTC）的灵活响应资源承包商，以支持国家心脏，肺和血液研究所（NHLBI）的科学转向研究翻译和治疗（SMARTT）计划。SMARTT计划的目的是提供资源，如咨询，制造，药理学和毒理学测试，临床前和早期临床研究设计支持，以及行政和监管专业知识，以协助将科学界出现的用于治疗心脏，肺和血液疾病的新型合成，自然或生物治疗干预措施转化为临床。